Ushbu ishga iqtibos qilgan ishlar

6 ta ish

Ish: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaTuberculosis Research and EpidemiologyNew England Journal of Medicine20225 iqtibos

   ABIABI:AkademIndex/openalex/2022.article.000002

2. Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

   Aastha Gupta, Sandeep Juneja, Victor Babawale +12

   MaqolaTuberculosis Research and EpidemiologyPLoS ONE20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000247

3. Introducing BPaL: Experiences from countries supported under the LIFT-TB project

   D. F. Wares, M. Mbenga, Veriko Mirtskhulava +19

   MaqolaTuberculosis Research and EpidemiologyPLoS ONE20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000471

4. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000869

5. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000230

6. Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study

   Karen Lowton, Beverley Stringer, M. Cusinato +7

   MaqolaTuberculosis Research and EpidemiologyIJTLD OPEN20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.016746